SCHEMBL6007433

SCHEMBL6007433

O=CNCc1cccc2nc3ccccc3nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.43
ADH1C P00326 1/20 0.43
ADH1A P07327 1/20 0.43
ADH7 P40394 1/20 0.43
ALDH1A1 P00352 5/20 0.42
MAPT P10636 4/20 0.42
KMT2A Q03164 3/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NQO2 P16083 1/20 0.39
MEN1 O00255 2/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
TERT O14746 2/20 0.35
ACHE P22303 2/20 0.33
KDM4E B2RXH2 1/20 0.33
PABPC1 P11940 1/20 0.33
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6008068 0.83 MAPT (0.42) ALDH1A1MAPTKMT2ARAB9AGAA
SCHEMBL6006432 0.78 KMT2A (0.47) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL6007426 0.77 MAPT (0.42) ALDH1A1MAPTKMT2ARAB9AGAA
SCHEMBL8763191 0.75 ADH1B (0.62) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL30595834 0.75 ADH1B (0.62) ADH1BADH1CADH1AADH7ALDH1A1
SCHEMBL3329528 0.75 MTNR1B (0.39) ALDH1A1MAPTRAB9AGAANPSR1
SCHEMBL3414003 0.74 NQO2 (0.50) ALDH1A1MAPTKMT2ARAB9AGAA
SCHEMBL9934669 0.74 MAPT (0.50) ALDH1A1MAPTKMT2ARAB9AGAA
SCHEMBL28567772 0.73 NQO2 (0.42) ALDH1A1MAPTKMT2ARAB9AGAA
SCHEMBL6008063 0.73 MAPT (0.42) ALDH1A1MAPTKMT2ARAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 ADH1B 372/4885ADH1C 89/4885ADH1A 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.